Peptide-based positron emission tomography probes: Current strategies for synthesis and radiolabelling

M Failla, G Floresta, V Abbate - RSC Medicinal Chemistry, 2023 - pubs.rsc.org
In medical imaging, techniques such as magnetic resonance imaging, contrast-enhanced
computerized tomography, and positron emission tomography (PET) are extensively …

Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using 211At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor …

S Qin, Y Yang, J Zhang, Y Yin, W Liu… - Molecular …, 2023 - ACS Publications
Small cell lung cancer (SCLC) is a neuroendocrine tumor with a high degree of malignancy.
Due to limited treatment options, patients with SCLC have a poor prognosis. We have found …

[HTML][HTML] Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside

C Van Laere, M Koole, CM Deroose… - Theranostics, 2024 - ncbi.nlm.nih.gov
Terbium features four clinically interesting radionuclides for application in nuclear medicine:
terbium-149, terbium-152, terbium-155, and terbium-161. Their identical chemical properties …

Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy

CN Funeh, J Bridoux, T Ertveldt, TWM De Groof… - Pharmaceutics, 2023 - mdpi.com
The precise delivery of cytotoxic radiation to cancer cells through the combination of a
specific targeting vector with a radionuclide for targeted radionuclide therapy (TRT) has …

Design and synthesis of a new bifunctional chelating agent: Application for Al 18F/177Lu complexation

W Laurène, L Raúl, S Katalin, F Céline, K Gilles… - Journal of Inorganic …, 2023 - Elsevier
Theranostic and personalized medicine are blooming strategies to improve oncologic
patients' health care and facilitate early treatment. While 18 F-radiochemistry for theranostic …

[HTML][HTML] Targeted radiopharmaceuticals: an underexplored strategy for ovarian cancer

M Crabbé, T Opsomer, K Vermeulen, M Ooms… - …, 2024 - pmc.ncbi.nlm.nih.gov
Ovarian cancer is the most common gynecological malignancy worldwide with the highest
mortality. This low survival rate can be attributed to the fact that symptoms arise only at an …

[HTML][HTML] Direct comparison of [18F] AlF-NOTA-JR11 and [18F] AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist

S Ahenkorah, C Cawthorne, E Murce… - Nuclear Medicine and …, 2023 - Elsevier
Abstract Background [18 F] AlF-NOTA-octreotide is an 18 F-labeled somatostatin analogue
which is a good clinical alternative for 68 Ga-labeled somatostatin analogues. However …

Pharmacokinetic Positron Emission Tomography Imaging of an Optimized CD38-Targeted 68Ga-Labeled Peptide in Multiple Myeloma: A Pilot Study

Q Yang, L Song, Z Chen, Y Qiu, T Wang… - Bioconjugate …, 2024 - ACS Publications
Multiple myeloma (MM) is an incurable disease characterized by its clinical and prognostic
heterogeneity. Despite conventional chemotherapy and autologous hematopoietic stem cell …

Complete remissions of HER2-positive trastuzumab-resistant xenografts using a potent [225Ac] Ac-labeled anti-HER2 antibody-drug radioconjugate

J Pougoue Ketchemen, FN Njotu… - Clinical Cancer …, 2024 - aacrjournals.org
Purpose: There is overwhelming interest to use actinium-225 ([225Ac] Ac) to develop
targeted alpha therapies. Antibody-drug conjugates (ADCs) are highly cytotoxic. Combining …

Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer

J Pougoue Ketchemen, FN Njotu, H Babeker… - European Journal of …, 2024 - Springer
Purpose To evaluate the imaging and therapeutic properties (theranostic) of 67Cu-labeled
anti-human epidermal growth factor receptor II (HER2) monoclonal antibody trastuzumab …